AHMEDABAD / MUMBAI / RAJKOT - In a regulatory update as submitted to the Indian Stock Exchanges, Ahmedabad headquartered Pankaj Patel led healthcare services and pharma & wellness products manufacturing Zydus Group's flagship company Cadila Healthcare Ltd said of having got USFDA (US Food & Drugs Administration) nod to sell medicine to treat excess iron deposits in human blood and helps treat blood disorder.
In a press-release titled, "Zydus Cadila receives final approval from USFDA for Deferasirox Tablets", as attached and enclosed with the regulatory filing as submitted by the company to the Indian Bourses, it further read that, Zydus Cadila has received final approval from the USFDA to market Deferasirox Tablets (US RLD: Jadenu™ Tablets) in the strengths of 90 mg, 180 mg and 360 mg.
Deferasirox binds to iron and removes it from the bloodstream. It is used to treat iron overload caused by blood transfusions in adults and children who are at least 2 years old.
It is also used to treat chronic iron overload syndrome caused by a genetic blood disorder (non-transfusion dependent thalassemia) in adults and children who are at least 10 years old.
The drug will be manufactured at the group’s manufacturing facility at SEZ, Anmedabad.
The group now has 291 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
In case, if you wish to VERIFY, the above narrated news-report, please CLICK here.
You can also access and/or read the above narrated news-report on our WEBSITE.
No comments:
Post a Comment